BusinessMelinta Therapeutics Reports First Quarter 2018 Financial ResultsBy Nasdaq OMXMay 8, 2018, 8:02 PM UTC
BusinessMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual MeetingBy Nasdaq OMXMay 8, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant BacteriaBy Nasdaq OMXMay 7, 2018, 11:00 AM UTC
BusinessSummit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018By Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessSummit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against GonorrhoeaBy Nasdaq OMXMar 13, 2018, 11:01 AM UTC
BusinessConnexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient SafetyBy Nasdaq OMXFeb 28, 2018, 3:13 PM UTC
BusinessNew Study Identifies Successful Approaches to Antimicrobial Stewardship Programs in U.S. HospitalsBy Nasdaq OMXJan 25, 2018, 6:00 PM UTC
BusinessMelinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease PortfolioBy Nasdaq OMXJan 8, 2018, 12:01 PM UTC
